> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alnylam Pharma Awarded Priority Review Voucher
- URL: https://www.fdaweb.com/alnylam-pharma-awarded-priority-review-voucher/
- Published: 2021-02-12T12:00:00.000Z
- Updated: 2026-09-14T16:46:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148657

*Federal Register* notice: FDA has issued a priority review voucher to Alnylam Pharmaceuticals in response to its rare pediatric disease product application for Oxlumo (lumasiran) injection, indicated for treating primary hyperoxaluria Type 1 to lower urinary oxalate levels in pediatric and adult patients. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-03012.pdf?ref=fdaweb.com).